The US Army has nearly run down its stockpile of long-range precision missiles, including Precision Strike Missiles and ATACMS, amid its ongoing conflict with Iran, NPR reports. These weapons allow strikes from hundreds of miles away, reducing risk to pilots, but replenishing them can take years, raising concerns about America's preparedness for future conflicts and its ability to support allies such as Ukraine. Separately, the US Food and Drug Administration is weighing approval of the first flu vaccine to use mRNA technology, developed by Moderna.

Patriot missile interceptor stocks have fallen by two-thirds since the war with Iran began, with each interceptor costing around $4 million to replace; officials say current supplies meet immediate needs but warn of vulnerability down the line. On the vaccine front, Moderna's shot, mFlusiva, was tested in a 40,000-person trial that found it safe and more effective than traditional flu jabs for adults aged 50 and over, with independent FDA advisers unanimously recommending approval in June; the mRNA platform also allows faster reformulation against new flu strains, though public scepticism lingers following controversies over COVID-19 vaccine mandates.